7-((1R,2S,3R,4S)-3-Pyridin-3-yl-7-oxa-bicyclo[2.2.1]hept-2-yl)-heptanoic acid | 133870-70-9

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: 7-((1R,2S,3R,4S)-3-Pyridin-3-yl-7-oxa-bicyclo[2.2.1]hept-2-yl)-heptanoic acid
• 英文别名: 7-[(1R,2S,3R,4S)-3-pyridin-3-yl-7-oxabicyclo[2.2.1]heptan-2-yl]heptanoic acid
• CAS: 133870-70-9
• 化学式: C₁₈H₂₅NO₃
• 分子量: 303.401
• InChiKey: ABLWTJQIUDQCME-CBZIJGRNSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  22
• 可旋转键数：
  8
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  59.4
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  3-(3-吡啶基)丙炔酸甲酯 在 palladium on activated charcoal sodium hydroxide 、 氯化亚砜 、 mercury(II) diacetate 、 氢气 、 二异丁基氢化铝 、 potassium 2-methylbutan-2-olate 、 potassium carbonate 作用下， 以 四氢呋喃 、 甲醇 、 乙醇 、 二氯甲烷 、 水 、 甲苯 为溶剂， -78.0~80.0 ℃ 、310.27 kPa 条件下， 反应 92.5h， 生成 7-((1R,2S,3R,4S)-3-Pyridin-3-yl-7-oxa-bicyclo[2.2.1]hept-2-yl)-heptanoic acid
  参考文献：
  名称：

  Thromboxane receptor antagonism combined with thromboxane synthase inhibition. 1. (.+-.)-(3-Pyridinylbicycloheptyl)alkanoic acids

  摘要：

  The design, synthesis, and in vitro pharmacology of a new class of compounds exerting both thromboxane receptor antagonist and thromboxane synthase inhibitory activities is described. [(3-Pyridinyl)bicycloheptyl]alkanoic acid 9 and its analogues, designed with the help of molecular modeling, were synthesized and found to be inhibitors of thromboxane A2 (TxA2) biosynthesis in a human platelet microsomal preparation. The compounds were also found to antagonize both platelet and vascular TxA2 receptors. The compounds inhibited the U 46619 induced aggregation of human washed platelets and platelet-rich plasma and the U 46619 induced contraction of the dog saphenous vein.

  DOI：

  10.1021/jm00110a006

文献信息

• Thromboxane receptor antagonism combined with thromboxane synthase inhibition. 1. (.+-.)-(3-Pyridinylbicycloheptyl)alkanoic acids
  作者：Shripad S. Bhagwat、Candido Gude、David S. Cohen、Warren Lee、Patricia Furness、Frank H. Clarke

  DOI：10.1021/jm00110a006

  日期：1991.6

  The design, synthesis, and in vitro pharmacology of a new class of compounds exerting both thromboxane receptor antagonist and thromboxane synthase inhibitory activities is described. [(3-Pyridinyl)bicycloheptyl]alkanoic acid 9 and its analogues, designed with the help of molecular modeling, were synthesized and found to be inhibitors of thromboxane A2 (TxA2) biosynthesis in a human platelet microsomal preparation. The compounds were also found to antagonize both platelet and vascular TxA2 receptors. The compounds inhibited the U 46619 induced aggregation of human washed platelets and platelet-rich plasma and the U 46619 induced contraction of the dog saphenous vein.